Uncategorized

September 9, 2019

Engage Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference

SUMMIT, N.J., Sept. 9, 2019 /PRNewswire/ — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an inhaled benzodiazepine for the abortive treatment of seizures in patients […]
August 14, 2019

Proof of Concept trial results for Staccato Alprazolam has neurology community cautiously optimistic

Speed of onset action is encouraging; additional research on other epilepsy patient subsets an important next step. Read more here: https://journals.lww.com/neurotodayonline/Pages/articleviewer.aspx?year=2019&issue=08080&article=00009&type=Fulltext
August 2, 2019

Engage Therapeutics CEO and Founder Greg Mayes selected to present at the 2020 Emerging MedTech Summit.

Greg Mayes, Engage Therapeutics’ CEO and Founder, will join other Life Science Intelligence leaders at the Ritz Carlton Laguna Niguel in Dana Point, CA February 18 […]
July 9, 2019

Engage Therapeutics Announces Data from Phase 2a, Proof-of-concept Study of Staccato Alprazolam to Suppress Seizures in Patients with Epilepsy Published in Epilepsia

This proof-of-concept study referenced in this peer-reviewed journal demonstrated that three doses of Staccato alprazolam (0.5 mg, 1.0 mg, and 2.0 mg) rapidly suppressed epileptic activity […]